About Enrich Biosystems
Enrich Biosystems is developing novel high-throughput, microfluidics-free cell discovery platforms that addresses critical gaps in existing technologies. Our technology enables more confident screening, isolation and discovery of cell therapy candidates, quick, easy and robust sample processing for single-cell omics analyses, and flexible cell line purification workflows. We are located in Branford, CT.
Executive Leadership
Dong Wang
Co-founder and CEO
Dong Wang
Co-founder and CEO
As Co-founder and Chief Executive Officer, Dong leads Enrich Biosystems in its mission to develop a highly integrated high-throughput cell imaging/analysis/capture platform and unleash its microfluidics-free technology to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Over the span of his 20 years career, Dong held various leadership positions in research, product, operation, and business development in various private and public life science companies, including Abcam, AxioMx, Illumina, and Affomix. Dong received both B.S. and M.S. degrees from University of Science and Technology Beijing and completed postgraduate training in Structural Biology at Cellular and Molecular Physiology Department of Yale University.
During his personal time, Dong enjoys playing soccer, traveling, and most importantly, spending quality time with his family.
Dr. Qi Zhao
Co-founder and CSO
Dr. Qi Zhao
Co-founder and CSO
Qi has a broad background in biology, physics and engineering, with specific training and expertise in key research areas for this application. In graduate school , he accomplished several challenging projects in virology, human DNA repair field, participated in a number of collaborations and further consolidate my skills in protein structure, computational biology and molecular biology. After joining AxioMx/Abcam Inc, he led and finished a number of clone screening platforms and several data-intensive rational library construction projects. He also authored and oversaw several NIH funded projects for new methods of developing function modulating antibodies against GPCR and enzymes. After Abcam, he co-founded Enrich to develop advanced phenotypical screening and evolution platforms. With the collaborated effort from biology and engineering, he constructed a number of functional cell libraries and invented devices to observe and capture functional phenotypes on crucial cells in immune oncology.
Dr. Xueqi Liu
Co-founder and VP of Engineering
Dr. Xueqi Li
Co-founder and VP of Engineering
Xueqi obtained his undergraduate and graduate training major in Biophysics at Tsinghua University in Beijing, where he studied macromolecule atomic structures and functions using X-crystallography technology. He did postdoc training in Yale University in Connecticut, where he researched on biological molecule functionalities using cutting-edge Cryo-Electron Microscopy. He also obtained a master’s degree major in Computer Science at University of New Haven, where he was motivated to pioneer in empowering biological and medical science using innovative interdisciplinary tools. He is enthusiastic about Enrich Biosystem’s unique science and technologies to accelerate therapeutic discoveries and human health care.
Kevin Leary
VP Sales and Marketing
Kevin Leary
VP Sales and Marketing
Kevin has over 20 years of successful commercial experience in market-leading and start-up life science research companies. Prior to joining Enrich Biosystems Inc., Kevin was a leading contributor in the commercial adoption of innovative solutions from Leica Microsystems, Perkin Elmer, ForteBio and others. His true motivation is making an impact on the success of his customers and drug development in general by advocating for the adoption of new technologies, especially Enrich Biosystems’ TROVO platform, that provide new and unique capabilities for more efficient and successful therapeutic discoveries.
In his free time, Kevin enjoys a variety of activities including sports, cooking, traveling and hiking with his family in Southbury, CT.
Board of Directors
Dong Wang
Co-founder and CEO
Dong Wang
Co-founder and CEO
As Co-founder and Chief Executive Officer, Dong leads Enrich Biosystems in its mission to develop a highly integrated high-throughput cell imaging/analysis/capture platform and unleash its microfluidics-free technology to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Over the span of his 20 years career, Dong held various leadership positions in research, product, operation, and business development in various private and public life science companies, including Abcam, AxioMx, Illumina, and Affomix. Dong received both B.S. and M.S. degrees from University of Science and Technology Beijing and completed postgraduate training in Structural Biology at Cellular and Molecular Physiology Department of Yale University.
During his personal time, Dong enjoys playing soccer, traveling, and most importantly, spending quality time with his family.
Dr. Qi Zhao
Co-founder and CSO
Dr. Qi Zhao
Co-founder and CSO
Qi has a broad background in biology, physics and engineering, with specific training and expertise in key research areas for this application. In graduate school , he accomplished several challenging projects in virology, human DNA repair field, participated in a number of collaborations and further consolidate my skills in protein structure, computational biology and molecular biology. After joining AxioMx/Abcam Inc, he led and finished a number of clone screening platforms and several data-intensive rational library construction projects. He also authored and oversaw several NIH funded projects for new methods of developing function modulating antibodies against GPCR and enzymes. After Abcam, he co-founded Enrich to develop advanced phenotypical screening and evolution platforms. With the collaborated effort from biology and engineering, he constructed a number of functional cell libraries and invented devices to observe and capture functional phenotypes on crucial cells in immune oncology.
Cyndi Green, PhD, MBA
Cynthia D. Green, PhD, MBA
Dr. Cynthia Green has over twenty-five years of life science experience in large biopharmaceutical, startup biotech companies, and venture investing. Cyndi is currently a venture partner at Connecticut Innovations, the state’s strategic venture capital arm and the leading source of financing and ongoing support for innovative, growing companies in Connecticut. Prior to joining CI, she led business development search and evaluation for anti-infectives and vaccines at Pfizer, where her technical leadership led to the formation of numerous companies, as well as acquisitions of various anti-infective franchises and vaccine portfolios. Cyndi is on the board of directors of BioCT and multiple companies, spanning therapeutics, research tools, digital imaging and other areas. Cyndi is active as a mentor and provides consultant expertise for a variety of organizations, including ABCT, eLabNYC, Springboard Enterprises and Endless Frontier Labs. Cyndi has a doctorate in molecular biology from SUNY Buffalo, did a postdoct at Yale and received an MBA from Rensselaer Polytechnic Institute.
Christopher K. McLeod
Christopher K. McLeod
Life Science Investor with CEO experience
Throughout his career, Christopher McLeod has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. Currently, Mr. McLeod is a managing partner at Elm Street Ventures, where he nurtures new ventures as an investor and advisor. He is a corporate director of three early stage companies.
In 2012, Mr. McLeod co-founded AxioMx, Inc., serving as President and CEO. AxioMx created technology to quickly develop custom antibodies for use in research and diagnostics. AxioMx was acquired by Abcam, plc in 2015.
Mr. McLeod served as President and Chief Executive Officer of 454 Life Sciences from February 2005 through September 2011, where he led the development, manufacturing and marketing of the company’s innovative DNA sequencing products, which are used in research laboratories worldwide. 454 Life Sciences was acquired by Roche Diagnostics in 2007.
Mr. McLeod earned his B.S. Magna Cum Laud with a dual major in economics and engineering and applied science from Yale University and his M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology.
Jay Teich
Jay Teich
Jay is an electrical engineer, serial entrepreneur, and now an investor and advisor to promising young companies primarily in life science instrumentation.
As Founder and CEO of Seahorse Bioscience, he and his team enabled scientists to visualize metabolic activity in living cells, creating new discoveries, a new market, and high growth leading to a sale to Agilent in 2016.
While investor and Director of Axion Bioscience, the company enabled a new field of study of electrical interactions among living cells and created a valuable business sold to Summa Equity in 2021.
Working with private equity firm Artemis Capital Partners, Jay supported the sale, growth and high-value re-sale of BioDot Inc, a leader in nanoliter scale liquid transfer systems for medical diagnostics in 2021.
In Jay’s first CEO role, he led a private equity buyout, rapid growth and high-value sale of Inframetrics Inc, manufacturer of high-performance thermal imaging systems for defense, industrial and life science applications.
Since engaging with Enrich in 2020, Jay has used his experience to help with strategy, fundraising, and KOL development.